4.89
price up icon4.49%   0.21
pre-market  Vorhandelsmarkt:  4.98   0.09   +1.84%
loading
Schlusskurs vom Vortag:
$4.68
Offen:
$4.7
24-Stunden-Volumen:
338.61K
Relative Volume:
0.62
Marktkapitalisierung:
$274.63M
Einnahmen:
$192.64M
Nettoeinkommen (Verlust:
$2.51M
KGV:
93.32
EPS:
0.0524
Netto-Cashflow:
$12.42M
1W Leistung:
+6.07%
1M Leistung:
+13.72%
6M Leistung:
+1.45%
1J Leistung:
-7.21%
1-Tages-Spanne:
Value
$4.6962
$4.90
1-Wochen-Bereich:
Value
$4.54
$4.95
52-Wochen-Spanne:
Value
$3.8092
$6.365

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name
Firmenname
Vanda Pharmaceuticals Inc
Name
Telefon
202-734-3400
Name
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Name
Mitarbeiter
368
Name
Twitter
Name
Nächster Verdiensttermin
2025-05-02
Name
Neueste SEC-Einreichungen
Name
VNDA's Discussions on Twitter

Vergleichen Sie VNDA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VNDA
Vanda Pharmaceuticals Inc
4.89 274.63M 192.64M 2.51M 12.42M 0.0524
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-31 Eingeleitet H.C. Wainwright Buy
2024-07-11 Eingeleitet Cantor Fitzgerald Overweight
2022-02-25 Herabstufung Jefferies Buy → Hold
2021-05-12 Eingeleitet BofA Securities Buy
2021-01-14 Herabstufung Citigroup Buy → Neutral
2020-10-29 Hochstufung Citigroup Neutral → Buy
2020-06-09 Herabstufung Citigroup Buy → Neutral
2020-03-16 Herabstufung Oppenheimer Perform → Underperform
2020-03-12 Hochstufung Citigroup Neutral → Buy
2019-11-07 Herabstufung Citigroup Buy → Neutral
2019-08-01 Hochstufung Citigroup Neutral → Buy
2019-07-25 Herabstufung Stifel Buy → Hold
2018-12-11 Herabstufung Oppenheimer Outperform → Perform
2018-12-04 Hochstufung Cantor Fitzgerald Neutral → Overweight
2018-12-04 Bestätigt Jefferies Buy
2018-11-08 Fortgesetzt Jefferies Buy
2018-09-21 Fortgesetzt Oppenheimer Outperform
2018-05-23 Eingeleitet Citigroup Buy
2018-01-19 Eingeleitet Seaport Global Securities Buy
2017-09-14 Bestätigt Piper Jaffray Overweight
2017-06-27 Fortgesetzt Piper Jaffray Overweight
2017-05-26 Eingeleitet H.C. Wainwright Buy
2017-04-12 Eingeleitet Oppenheimer Outperform
2016-11-09 Eingeleitet Aegis Capital Buy
2016-10-06 Fortgesetzt Jefferies Buy
Alle ansehen

Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten

pulisher
Jun 17, 2025

Insider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharm - GuruFocus

Jun 17, 2025
pulisher
Jun 13, 2025

DC Circ. Urged To Reject Approval For Braille-Free Drug Label - Law360

Jun 13, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - StreetInsider

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial E - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals (VNDA) Initiates First Human Trial for Ant - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda's Breakthrough: First-Ever Personalized Treatment Trial Launches for Ultra-Rare CMT2S Disease - Stock Titan

Jun 10, 2025
pulisher
Jun 09, 2025

Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow

Jun 09, 2025
pulisher
Jun 05, 2025

Vanda Approves Key Proposals at Annual Meeting - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow

Jun 05, 2025
pulisher
Jun 05, 2025

CLASS ACTION UPDATE for SPB, VNDA and ARA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 03, 2025

Class Action Reminder Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire

Jun 03, 2025
pulisher
May 29, 2025

Judge Favors Vanda But Seeks Deal Over Drug Approval - Law360

May 29, 2025
pulisher
May 27, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting | VNDA Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting - PR Newswire

May 27, 2025
pulisher
May 27, 2025

SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow

May 27, 2025
pulisher
May 27, 2025

Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan

May 27, 2025
pulisher
May 22, 2025

Justices Urged To Undo Denial Of Fast Track For Gastro Drug - Law360

May 22, 2025
pulisher
May 22, 2025

Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus

May 22, 2025
pulisher
May 21, 2025

President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow

May 21, 2025
pulisher
May 20, 2025

Insider Buying: Mihael Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus

May 20, 2025
pulisher
May 19, 2025

President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4) - Quantisnow

May 19, 2025
pulisher
May 18, 2025

Mystics enter new partnership with Vanda Pharmaceuticals - Monumental Sports Network

May 18, 2025
pulisher
May 17, 2025

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - The Malaysian Reserve

May 17, 2025
pulisher
May 16, 2025

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 | VNDA Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Mystics tap D.C.'s Vanda Pharmaceuticals as new jersey sponsor - The Business Journals

May 16, 2025
pulisher
May 16, 2025

Monumental Sports & Entertainment Announces Vanda Pharmaceuticals Inc. as Official Partner and Jersey Patch Partner for the Washington Mystics - Monumental Sports

May 16, 2025
pulisher
May 14, 2025

Vanda Pharmaceuticals (VNDA) Receives Overweight Rating from Can - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Vanda Pharmaceuticals (VNDA) Projected to Transform with Overwei - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Vanda Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald - TipRanks

May 14, 2025
pulisher
May 13, 2025

Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union | Libero Quotidiano.it - Libero Quotidiano

May 13, 2025
pulisher
May 10, 2025

Vanda Pharmaceuticals’ (VNDA) “Buy” Rating Reiterated at HC Wainwright - Defense World

May 10, 2025
pulisher
May 09, 2025

Vanda pharmaceuticals outlines $210M-$250M revenue target for 2025 amid product launches - MSN

May 09, 2025
pulisher
May 09, 2025

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 09, 2025
pulisher
May 08, 2025

Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges - TipRanks

May 08, 2025
pulisher
May 08, 2025

Vanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Vanda: Q1 Earnings Snapshot - MySA

May 08, 2025
pulisher
May 08, 2025

Vanda Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks

May 08, 2025
pulisher
May 07, 2025

Vanda Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.50 Beats - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Earnings call transcript: Vanda Pharmaceuticals misses Q1 2025 forecasts - Investing.com

May 07, 2025
pulisher
May 07, 2025

Capitals Announce Game 3 Watch Party at The Wharf as Part of Additional Playoffs Initiatives Presented by Vanda Pharmaceuticals Inc. - NHL.com

May 07, 2025
pulisher
May 07, 2025

Vanda Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.50 Beats Estimate, Revenue Surpasses Forecast at $50 Million - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Vanda Pharmaceuticals (VNDA) Reports Strong Q1 Revenue and Expands Product Pipeline | VNDA Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results - StreetInsider

May 07, 2025
pulisher
May 07, 2025

HC Wainwright & Co. Reiterates Buy Rating on Vanda Pharmaceutica - GuruFocus

May 07, 2025

Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):